Similar articles

• Why the Avandia scandal proves big pharma needs stronger ethical standards.

  Philpott S, Baker R. Philpott S, et al. Bioethics. 2010 Oct;24(8):ii-iii. doi: 10.1111/j.1467-8519.2010.01855.x. Bioethics. 2010. PMID: 21050246 No abstract available.
• Full disclosure.

  Maxwell D. Maxwell D. Can Fam Physician. 2008 Oct;54(10):1377-8; discussion 1378. Can Fam Physician. 2008. PMID: 18854458 Free PMC article. No abstract available.
• Getting more generous with the truth: clinical trial reporting in 2013 and beyond.

  Barbour V, Clark J, Connell L, Ross A, Simpson P, Veitch E, Winker M. Barbour V, et al. PLoS Med. 2013;10(1):e1001379. doi: 10.1371/journal.pmed.1001379. Epub 2013 Jan 29. PLoS Med. 2013. PMID: 23382657 Free PMC article.
• Cardiovascular risk of rosiglitazone: another perspective.

  Waksman JC. Waksman JC. J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. J Pharm Pharmacol. 2008. PMID: 19000361 Review.
• Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.

  Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Hernandez AV, et al. Am Heart J. 2008 Jul;156(1):23-30. doi: 10.1016/j.ahj.2008.03.002. Epub 2008 May 5. Am Heart J. 2008. PMID: 18585493 Review.